Trial Profile
An Exploratory Study to Evaluate [68Ga]ABY-025 for PET Imaging of HER2 Expression in Subjects With Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jul 2022
Price :
$35
*
At a glance
- Drugs Anti HER2 small molecule imaging agent (Primary)
- Indications Breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
- Focus Diagnostic use
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 08 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.